TC Biopharm (Holdings) Plc (TCBP) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Motherwell, 英国. 现任CEO为 Bryan Leland Kobel.
TCBP 拥有 IPO日期为 2022-02-11, 41 名全职员工, 在 NASDAQ Capital Marke, 市值为 $256.5K.
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
